Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
0.201
-0.003 (-1.67%)
Apr 29, 2026, 9:19 AM EDT - Market open

Liminatus Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-10.21-3.55-4.98-2.93-5.61
Depreciation & Amortization
0---0
Asset Writedown & Restructuring Costs
---0.90.9
Other Operating Activities
7.23---1.5
Change in Accounts Payable
-4.04-0.010.430.090.04
Change in Other Net Operating Assets
-2.952.111.211.073.01
Operating Cash Flow
-9.96-1.45-3.35-0.87-0.17
Capital Expenditures
-0.01----
Investing Cash Flow
-0.79-2.85-0.82--
Short-Term Debt Issued
4.343.923.419.44-
Total Debt Issued
4.343.923.419.44-
Short-Term Debt Repaid
-1.3--3.86-7.03-
Total Debt Repaid
-1.3--3.86-7.03-
Net Debt Issued (Repaid)
3.043.92-0.452.42-
Issuance of Common Stock
10.56--4.2-
Repurchase of Common Stock
----0.7-
Other Financing Activities
-2.56----
Financing Cash Flow
11.033.92-0.455.92-
Net Cash Flow
0.28-0.38-4.615.05-0.17
Free Cash Flow
-9.98-1.45-3.35-0.87-0.17
Free Cash Flow Per Share
-0.42-0.08-0.03-0.02-
Cash Interest Paid
---0.5-
Levered Free Cash Flow
7.14-2.92-2.3-0.67-
Unlevered Free Cash Flow
7.28-2.71-2.19-0.53-
Change in Working Capital
-6.982.11.641.163.05
Source: S&P Capital IQ. Standard template. Financial Sources.